News from annual scientific meetings around the world.
The randomised, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib…
Nathan Bahary, University of Pittsburgh With Alex Trebek’s recent announcement that his pancreatic cancer is…
Immunotherapy is a revolutionary cancer treatment, but it was unknown if cancer patients with HIV…
A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology…
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…
Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma…
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response…
A precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage…
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…
The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy…